Aromatase inhibitors and arthralgias: A new frontier in symptom management for breast cancer survivors

Journal of Clinical Oncology

Volumn 25, Issue 25, 2007, Pages 3797-3799

  Burstein, Harold J ^a   Winer, Eric P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ARTHRALGIA; ARTHRITIS; BONE ATROPHY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVOR; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; FRAGILITY FRACTURE; HUMAN; MUSCULOSKELETAL DISEASE; MYALGIA; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; SYMPTOM; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; COMORBIDITY; FEMALE; INCIDENCE; NOTE; SURVIVOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; ARTHRALGIA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; FEMALE; HUMANS; INCIDENCE; SURVIVORS;

EID: 34548539122     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.9529     Document Type: Editorial

References (14)

1. Winer EP, Hudis C, Burstein HJ, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone-receptor positive breast cancer: Status report 2004. J Clin Oncol 23:619-629, 2005
2. Chien AJ, Goss PE: Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 24:5305-5312, 2006
3. Hillner B, Ingle JN, Chlebowski R, et al: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003
4. Donnellan PP, Douglas SL, Cameron DA, et al: Aromatase inhibitors and arthralgias. J Clin Oncol 19:2767, 2001
5. Burstein HJ: Aromatase inhibitor associated arthralgia syndrome. Breast 16:223-234, 2007
6. Fallowfield L, Cella D, Cuzick J, et al: Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22:4261-4271, 2004
7. Whelan TJ, Goss PE, Ingle JN, et al: Assessment of quality of life in MA.17: A randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23:6931-6940, 2005
8. Fallowfield LJ, Bliss JM, Porter LS, et al: Quality of life in the intergroup exemestane study: A randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24:910-917, 2006
9. Crew KD, Greenlee H, Capodice J, et al: Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877-3883, 2007
10. Dent S, DeValentin T, Vandermeer L, et al: Long-term toxicities in women with early stage breast cancer treated with aromatase inhibitors: Data from a tertiary care center. Breast Cancer Res Treat 100:S190, 2006 (suppl 1; abstr 4057)
11. Azria D, Lamy PJ, Belkacemi Y, et al: Letrozole-induced arthralgia is not consistent with an autoimmune disease resembling Sjögren's syndrome: Preliminary results of a multicentric prospective trial. Breast Cancer Res Treat 100:S25, 2006 (suppl 1; abstr 106)
12. Felson DT, Cummings SR: Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52:2594-2598, 2005
13. Loprinzi CL, Duffy J, Ingle JN: Postchemotherapy rheumatism. J Clin Oncol 11:768-770, 1993
14. Morales L, Pans S, Paridaens R, et al: Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: Associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat [epub ahead of print on October 24, 2006]